On Sept. 22, 2016, Vanderbilt University Medical Center became the world’s first site to treat a prostate cancer therapy patient in the TULSA-PRO Ablation Clinical Trial (TACT). The TACT employed an emerging therapy that used MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation.